Teja Kumar Reddy Konatham

Mr. Teja Kumar Reddy Konatham


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Cellular, Molecular and Biomedical Reports
Verified
Journal Article
Open access
PDF file
TKTeja Kumar Reddy Konatham
Teja Kumar Reddy Konatham
ARAlapati Sahithi Reddy
Alapati Sahithi Reddy
Targeted drug delivery systems have emerged as promising approaches for improving the efficacy and safety of cancer therapy. This review highlights recent advancements in drug delivery technologies aimed at achieving targeted and personalized treatment strategies for cancer patients. The integration of nanotechnology, biomaterials, and molecular targeting strategies has enabled the development of sophisticated drug delivery systems capable of selectively delivering therapeutic agents to tumour tissues while minimizing off-target effects on healthy tissues. Various targeting mechanisms, including passive and active targeting strategies, exploit the unique physiological characteristics of tumours, such as abnormal vasculature, overexpressed receptors, and altered microenvironments, to achieve selective accumulation and retention of drugs within tumour tissues. Nanoparticle-based drug delivery systems, such as liposomes, polymeric nanoparticles, and inorganic nanoparticles, offer advantages in terms of drug loading capacity, sustained release, and tumour targeting, making them attractive platforms for targeted cancer therapy. Moreover, the integration of smart drug delivery systems that respond to specific stimuli within the tumor microenvironment, such as pH, temperature, or enzyme activity, holds promise for enhancing tumor specificity and reducing systemic toxicity. Combination therapy approaches, which combine targeted drug delivery with other therapeutic modalities, such as immunotherapy or photodynamic therapy, offer synergistic effects and opportunities for overcoming treatment resistance. Despite these advancements, several challenges remain, including the translation of preclinical research findings into clinically viable therapies, regulatory approval, manufacturing scalability, and biomarker discovery. Addressing these challenges and embracing innovative approaches will be essential for realizing the full potential of targeted drug delivery systems in improving patient outcomes and advancing cancer therapy.

1 February 2023 in Separations
Verified
Journal Article
Open access
PDF file
SYSuresh Reddy Yelampalli
Suresh Reddy Yelampalli
KGKUMARASWAMY GANDLA GANDLA
KUMARASWAMY GANDLA GANDLA
TKTeja Kumar Reddy Konatham
Teja Kumar Reddy Konatham
AIAdel Ibrahim
Adel Ibrahim
Sami El DeebSami El Deeb
Sami El Deeb
An ion chromatography technique with conductivity detection was selected as an analytical tool for the simultaneous indirect determination of sodium sulfate, potassium sulfate, and magnesium sulfate via their respective cations. The method was developed and validated for the quantitative assay of the inorganic salts under study in oral pharmaceutical dosage forms. Chromatographic separation was achieved on a Dionex®IonPac® CS16 column (250 × 5 mm) column using the gradient elution method. A mobile phase-A consisting of methane sulfonic acid (6.7%, v/v) in Milli-Q water, which is used together with Milli-Q water, was used as a mobile Phase-B. The flow rate was 1.2 mL/min. The retention times of sodium, potassium, and magnesium as sulfates were 7.8, 12.8, and 16.2 min, respectively. The method was validated according to ICH guidelines and showed good linearity and accuracy results within concentration ranges of 80.0–240.0, 20.0–60.0, and 4.5–13.5 ppm for sodium, potassium, and magnesium as sulfates, respectively. The relative standard deviation results for intra- and inter-day precision were less than 1.0%. The method was applied successfully for determination of the analytes under study in their mixed pharmaceutical oral solution and found suitable for their routine and stability analysis.

7 July 2022 in International journal of health sciences
Verified
Journal Article
Open access
PDF file
TKTeja Kumar Reddy Konatham
Teja Kumar Reddy Konatham
MHM. Akiful Haque
M. Akiful Haque
A satisfactory LC-MS/MS separation and good peak symmetry for Atrasentan were obtained with Agilent, Zorbax, XDB C18 (2.1 x 50 mm ID, 5 μm), and a mobile phase containing a mixture of 5 mM Ammonium Formate buffer with 0.1% formic acid were mixed with HPLC grade Acetonitrile in the proportion of 70:30, v/v was delivered at a flow rate of 0.150 mL/min by positive ion mode (API 4000) with an injection volume of 10 µL and a run time of 3 min. Detection is performed by atmospheric pressure electrospray ionization (ESI) mass spectrometry in positive ion mode. The precursor to product ion transitions is m/z 5.11.600 to 354.04 for Atrasentan, and m/z 455.40 to 165.00 for Verapamil (Internal standard) were used for quantization. The retention time of Atrasentan and Verapamil (Internal standard) was found to be 1.68 & 0.96 min.

25 March 2024 in International Journal of Pharmaceutical Quality Assurance
Verified
Journal Article
Open access
TKTeja Kumar Reddy Konatham
Teja Kumar Reddy Konatham
MHMa Haque
Ma Haque

1 March 2025 in Cellular, Molecular and Biomedical Reports
Verified
Journal Article
Open access
PDF file
SKSudha Divya Madhuri Kallam
Sudha Divya Madhuri Kallam
ABAnoop Bodapati
Anoop Bodapati
ARAlapati Sahithi Reddy
Alapati Sahithi Reddy
TKTeja Kumar Reddy Konatham
Teja Kumar Reddy Konatham
Monoclonal antibodies (mAbs) represent a cornerstone of modern therapeutic strategies, targeting a wide array of diseases with unprecedented specificity. Developing and validating bioanalytical methods for mAbs are critical to ensuring their efficacy, safety, and regulatory compliance. This review discusses the recent advances in bioanalytical technologies and the persistent challenges faced in the field. Significant progress has been made in chromatographic techniques, mass spectrometry, and capillary electrophoresis, enhancing the analysis of mAbs in terms of resolution, sensitivity, and throughput. Innovations such as high-resolution mass spectrometry and automated capillary electrophoresis systems have transformed the mAb characterization landscape. However, challenges remain, primarily due to the complex nature of mAbs, which necessitates the development of susceptible and specific methods to determine their pharmacokinetic profiles and detect low-abundance impurities accurately. Moreover, the stringent and evolving regulatory requirements demand robust and reproducible analytical methods. This review emphasizes the need for continuous technological innovation and adaptation to address these challenges effectively.

17 September 2024 in SN Computer Science
Verified
Journal Article
Closed access
PDF file
ATAnil Kumar Tallam
Anil Kumar Tallam
TKTeja Kumar Reddy Konatham
Teja Kumar Reddy Konatham
UPUttam Prasad Panigrahy
Uttam Prasad Panigrahy
ASAlapati Sahithi
Alapati Sahithi
SPS. Prema
S. Prema
RCR S Chandan Chandan
R S Chandan Chandan